

In non-EU member Norway, the Norwegian Institute of Public Health urged young people under 30 to opt for the Pfizer vaccine "due to an increased risk of a rare side effect" with Moderna. It said that data show that there is a suspicion of an increased risk of heart inflammation when vaccinated with Moderna shots, although the number of cases of heart inflammation remains very low. In Denmark, people under 18 won't be offered the Moderna vaccine out of precaution, the Danish Health Authority said Wednesday. Its decision to suspend the Moderna vaccine is valid until Dec. The Swedish agency said the vaccine from Pfizer is recommended for these age groups instead. "The increase in risk is seen within four weeks after the vaccination, mainly within the first two weeks," it said. The preliminary Nordic analysis indicate that the connection is especially clear when it comes to Moderna's vaccine, especially after the second dose, the agency said. In 2019, approximately 300 people under the age of 30 were treated in hospital with myocarditis.ĭata point to an increased incidence also in connection with vaccination against COVID-19, mainly in adolescents and young adults and mainly in boys and men. The conditions are most common among young men, in connection with, for example, viral infections such as Covid-19. Swedish health authorities said the heart symptoms "usually go away on their own," but they must be assessed by a doctor. US and European regulators cautioned, however, that both the Moderna and Pfizer vaccines appear linked to a rare reaction in teenagers and young adults - chest pain and heart inflammation. Sore arms, headache and fatigue were the most common side effects in young vaccine recipients, the same ones as for adults. In a study of more than 3,700 children aged 12 to 17, the vaccine triggered the same signs of immune protection, and no Covid-19 diagnoses arose in the vaccinated group compared with four cases among those given dummy shots. Hundreds of millions of Moderna doses already have been administered to adults.


The Pfizer/BioNTech vaccine is cleared for people 12 and older in Europe and North America. Canada also recently approved its use for those as young as 12. In July, the European Medicines Agency recommended authorizing Moderna's Covid-19 vaccine for children ages 12 to 17, the first time that shot was cleared for anyone under 18. The final results were expected in about a month, said Bolette Soeborg of the Danish government health agency.Moderna's vaccine was given the green light for use in anyone 18 and over across the 27-nation European Union in January. The study was conducted by Denmark's Statens Serum Institut, a government agency that maps the spread of the coronavirus in the country the Medical Products Agency in Sweden Norway's National Institute of Public Health and the Institute for Health and Welfare in Finland. The preliminary information from the Nordic study has been sent to the European Medicines Agency's adverse reaction committee to be assessed. People born 1991 or later that had received a first Moderna shot, some 81,000 people, would not get a second Moderna jab, it added.Īnders Tegnell, Sweden's chief epidemiologist, said they "follow the situation closely and act quickly to ensure that vaccinations against Covid-19 are always as safe as possible and at the same time provide effective protection" against the disease. The Swedish health agency said it now recommended the Comirnaty vaccine from Pfizer/BioNtech instead. It added: “The risk of being affected is very small.” Authorities in Finland are expected to make a decision on the matter on Thursday, according to chief physician at the Finnish Institute for Health and Welfare Dr Hanna Nohynek.Īll three countries based their decision on an unpublished study with Sweden’s Public Health Agency saying that it signals “an increased risk of side effects such as inflammation of the heart muscle or the pericardium” - the double-walled sac containing the heart and the roots of the main vessels.
